A recent Phase I clinical trial has revealed that FOR46, an experimental antibody-drug conjugate targeting the CD46 protein, demonstrates promising efficacy in treating metastatic castration-resistant prostate cancer (mCRPC).
Among patients treated at doses of 1.2 mg/kg or higher, the median radiographic progression-free survival was 8.7 months. Additionally, 36% of evaluable patients experienced a PSA50 response, indicating a significant reduction in prostate-specific antigen levels, and the confirmed objective response rate was 20%. These findings suggest that FOR46 may offer a new therapeutic option for patients with advanced prostate cancer.
Predicting Response to Bipolar Androgen Therapy - A Blood Based Biomarker Approach
Seminal Vesicle Invasion & Senescent tumor cells.
